Pathogenesis of differentiated thyroid cancer (papillary and follicular)
Autor(a) principal: | |
---|---|
Data de Publicação: | 2005 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Arquivos Brasileiros de Endocrinologia & Metabologia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302005000500009 |
Resumo: | Differentiated thyroid cancers (papillary - PTC and follicular - FTC) are the most common endocrine malignancies. The recent progresses in the understanding of PTC and FTC pathogenesis are summarized in this review. In PTC, a single mutation of BRAF (the gene for the B-type Raf kinase) (V600E) is responsible for the disease in 40-50% of patients, especially in older people and is associated with a poorer clinicopathological outcome. Due to these characteristics, its use as a specific diagnostic and prognostic marker for PTC in cytological specimens is being implemented. Another important cause of PTC is rearrangements of the RET tyrosine kinase receptor (RET/PTC), which represent a recombination of the promoter and N-terminal domain of a partner gene with the C-terminal region of the RET gene, resulting in a chimeric gene with a protein product containing a constitutively activated RET tyrosine kinase, responsible for 20-30% patients, specially the younger or after radiation. The pathogenesis of FTC is less understood. A chromosomal translocation between the transcription factor PAX8 and the peroxisome proliferator-activated receptorgamma (PPARgamma) occurs in 30-50% of patients; however, the presence of PAX8-PPARgamma is also demonstrated in follicular adenomas. Therefore, there is no complete evidence that PAX8-PPARgamma is the cause of FTC. Another finding in FTC is mutations on the RAS gene, which excludes PAX8-PPARgamma rearrangements. Several genes, as TRgamma, PTEN, PKAR1A, DDIT3, ARG2, ITM1 and C1orf24 - some discovered by techniques of differential gene expression -, have been recently implicated in the pathogenesis of FTC. |
id |
SBEM-2_b7c5669400711f7f8bebc40089018886 |
---|---|
oai_identifier_str |
oai:scielo:S0004-27302005000500009 |
network_acronym_str |
SBEM-2 |
network_name_str |
Arquivos Brasileiros de Endocrinologia & Metabologia (Online) |
repository_id_str |
|
spelling |
Pathogenesis of differentiated thyroid cancer (papillary and follicular)Papillary thyroid carcinomaFollicular thyroid carcinomaRET; BRAF; RET/PTC; RAS; PAX8/PPARgammaDifferentiated thyroid cancers (papillary - PTC and follicular - FTC) are the most common endocrine malignancies. The recent progresses in the understanding of PTC and FTC pathogenesis are summarized in this review. In PTC, a single mutation of BRAF (the gene for the B-type Raf kinase) (V600E) is responsible for the disease in 40-50% of patients, especially in older people and is associated with a poorer clinicopathological outcome. Due to these characteristics, its use as a specific diagnostic and prognostic marker for PTC in cytological specimens is being implemented. Another important cause of PTC is rearrangements of the RET tyrosine kinase receptor (RET/PTC), which represent a recombination of the promoter and N-terminal domain of a partner gene with the C-terminal region of the RET gene, resulting in a chimeric gene with a protein product containing a constitutively activated RET tyrosine kinase, responsible for 20-30% patients, specially the younger or after radiation. The pathogenesis of FTC is less understood. A chromosomal translocation between the transcription factor PAX8 and the peroxisome proliferator-activated receptorgamma (PPARgamma) occurs in 30-50% of patients; however, the presence of PAX8-PPARgamma is also demonstrated in follicular adenomas. Therefore, there is no complete evidence that PAX8-PPARgamma is the cause of FTC. Another finding in FTC is mutations on the RAS gene, which excludes PAX8-PPARgamma rearrangements. Several genes, as TRgamma, PTEN, PKAR1A, DDIT3, ARG2, ITM1 and C1orf24 - some discovered by techniques of differential gene expression -, have been recently implicated in the pathogenesis of FTC.Sociedade Brasileira de Endocrinologia e Metabologia2005-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302005000500009Arquivos Brasileiros de Endocrinologia & Metabologia v.49 n.5 2005reponame:Arquivos Brasileiros de Endocrinologia & Metabologia (Online)instname:Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)instacron:SBEM10.1590/S0004-27302005000500009info:eu-repo/semantics/openAccessMaciel,Rui M.B.Kimura,Edna T.Cerutti,Janete M.eng2006-01-23T00:00:00Zoai:scielo:S0004-27302005000500009Revistahttps://www.aem-sbem.com/ONGhttps://old.scielo.br/oai/scielo-oai.php||abem-editoria@endocrino.org.br1677-94870004-2730opendoar:2006-01-23T00:00Arquivos Brasileiros de Endocrinologia & Metabologia (Online) - Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)false |
dc.title.none.fl_str_mv |
Pathogenesis of differentiated thyroid cancer (papillary and follicular) |
title |
Pathogenesis of differentiated thyroid cancer (papillary and follicular) |
spellingShingle |
Pathogenesis of differentiated thyroid cancer (papillary and follicular) Maciel,Rui M.B. Papillary thyroid carcinoma Follicular thyroid carcinoma RET; BRAF; RET/PTC; RAS; PAX8/PPARgamma |
title_short |
Pathogenesis of differentiated thyroid cancer (papillary and follicular) |
title_full |
Pathogenesis of differentiated thyroid cancer (papillary and follicular) |
title_fullStr |
Pathogenesis of differentiated thyroid cancer (papillary and follicular) |
title_full_unstemmed |
Pathogenesis of differentiated thyroid cancer (papillary and follicular) |
title_sort |
Pathogenesis of differentiated thyroid cancer (papillary and follicular) |
author |
Maciel,Rui M.B. |
author_facet |
Maciel,Rui M.B. Kimura,Edna T. Cerutti,Janete M. |
author_role |
author |
author2 |
Kimura,Edna T. Cerutti,Janete M. |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Maciel,Rui M.B. Kimura,Edna T. Cerutti,Janete M. |
dc.subject.por.fl_str_mv |
Papillary thyroid carcinoma Follicular thyroid carcinoma RET; BRAF; RET/PTC; RAS; PAX8/PPARgamma |
topic |
Papillary thyroid carcinoma Follicular thyroid carcinoma RET; BRAF; RET/PTC; RAS; PAX8/PPARgamma |
description |
Differentiated thyroid cancers (papillary - PTC and follicular - FTC) are the most common endocrine malignancies. The recent progresses in the understanding of PTC and FTC pathogenesis are summarized in this review. In PTC, a single mutation of BRAF (the gene for the B-type Raf kinase) (V600E) is responsible for the disease in 40-50% of patients, especially in older people and is associated with a poorer clinicopathological outcome. Due to these characteristics, its use as a specific diagnostic and prognostic marker for PTC in cytological specimens is being implemented. Another important cause of PTC is rearrangements of the RET tyrosine kinase receptor (RET/PTC), which represent a recombination of the promoter and N-terminal domain of a partner gene with the C-terminal region of the RET gene, resulting in a chimeric gene with a protein product containing a constitutively activated RET tyrosine kinase, responsible for 20-30% patients, specially the younger or after radiation. The pathogenesis of FTC is less understood. A chromosomal translocation between the transcription factor PAX8 and the peroxisome proliferator-activated receptorgamma (PPARgamma) occurs in 30-50% of patients; however, the presence of PAX8-PPARgamma is also demonstrated in follicular adenomas. Therefore, there is no complete evidence that PAX8-PPARgamma is the cause of FTC. Another finding in FTC is mutations on the RAS gene, which excludes PAX8-PPARgamma rearrangements. Several genes, as TRgamma, PTEN, PKAR1A, DDIT3, ARG2, ITM1 and C1orf24 - some discovered by techniques of differential gene expression -, have been recently implicated in the pathogenesis of FTC. |
publishDate |
2005 |
dc.date.none.fl_str_mv |
2005-10-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302005000500009 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302005000500009 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S0004-27302005000500009 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Endocrinologia e Metabologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Endocrinologia e Metabologia |
dc.source.none.fl_str_mv |
Arquivos Brasileiros de Endocrinologia & Metabologia v.49 n.5 2005 reponame:Arquivos Brasileiros de Endocrinologia & Metabologia (Online) instname:Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) instacron:SBEM |
instname_str |
Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) |
instacron_str |
SBEM |
institution |
SBEM |
reponame_str |
Arquivos Brasileiros de Endocrinologia & Metabologia (Online) |
collection |
Arquivos Brasileiros de Endocrinologia & Metabologia (Online) |
repository.name.fl_str_mv |
Arquivos Brasileiros de Endocrinologia & Metabologia (Online) - Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) |
repository.mail.fl_str_mv |
||abem-editoria@endocrino.org.br |
_version_ |
1754734808018190336 |